SGLT2 Inhibitors Linked to Lower Dementia Risk in Psychiatric Patients, Study Suggests

A large Veterans Affairs (VA) cohort study, published in JAMA Network Open, indicates that SGLT2 inhibitor use is associated with a lower risk of dementia and fewer psychiatric emergency department visits in older adults with major depressive disorder, bipolar disorder, or schizophrenia spectrum disorder. The study, involving over 112,000 patients, found a 39% lower relative odds of incident all-cause dementia with SGLT2 inhibitor initiation, suggesting potential benefits beyond cardiometabolic disease and supporting shared metabolic mechanisms between psychiatric illness and neurodegeneration.

Context

SGLT2 inhibitors are primarily used to manage diabetes and have shown cardiovascular benefits. Previous research has linked psychiatric disorders with increased dementia risk, suggesting shared biological pathways. This study, conducted by the Veterans Affairs health system, analyzed data from over 112,000 patients to explore the relationship between SGLT2 inhibitors and dementia risk in this vulnerable population.

Why it matters

This study highlights a potential new avenue for reducing dementia risk among older adults with serious psychiatric conditions. As dementia rates rise globally, identifying effective preventive measures is crucial. The findings may influence treatment strategies for patients with major depressive disorder, bipolar disorder, or schizophrenia spectrum disorder, potentially improving their overall health outcomes.

Implications

If SGLT2 inhibitors are proven effective in reducing dementia risk, it could lead to changes in prescribing practices for psychiatric patients. This could improve the quality of life for many individuals facing both psychiatric and neurodegenerative challenges. Additionally, healthcare systems may see shifts in resource allocation and management strategies for aging populations with complex health needs.

What to watch

Further research may be conducted to confirm these findings and explore the mechanisms behind the observed effects. Healthcare providers may begin to consider SGLT2 inhibitors as part of treatment plans for psychiatric patients at risk of dementia. Monitoring guidelines and recommendations from health organizations could evolve based on emerging evidence.